OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Advances in Hematopoietic Stem Cell Transplantation
Submission Deadline: March 15, 2022 (Open) Submit Now
Alessandra Picardi, PhD
1. Università degli Studi di Roma "Tor Vergata", Rome, Italy.
2. Director of Haematology and Stem Cell Transpant Unit of AORN Cardarelli, Naples, Italy.
Research Interests: Allogeneic Stem cell transplantation; Haematopoietic Stem Cell Donors; Autologous Stem Cell Transplantation
About This Topic
Hematopoietic Stem Cell Transplantation (HSCT) represents a therapeutic option for several neoplastic and non neoplastic haematological diseases. Many discoveries have been made in the last decades both in the autologous and allogeneic setting. Nowadays, the toxicity of the autologous HSCT is limited to a very small proportion of patients with a non relapse mortality rate < 5%, regardless the patient’s age. The new antibotics and antifungal drugs reduced the infectious mortality even in patients colonized by multi-resistant germs. The EBMT and CIBMTR activity survey of 2019 counts 25018 and 14270 autologous HSCT in 700 and 190 transplant teams, respectively.
Moreover, the advances in the supportive care, the modulation of the conditioning regimens, the better graft versus host disease (GVHD) control toghether with a wider donor’s choice has also increased the safety and the application of allogeneic HSCT. Thanks to theese progresses, even elderly up to 75-80 years perform the allogeneic HSCT and a suitable donor may be identified for almost all patients. The EBMT and CIBMTR activity survey of 2019 counts 18563 and 9498 first allogeneic HSCT, respectively. In the United States, it is worth to note that in 2019, 26% of allogeneic transplant recipients were age 65 and older.
In this context, the aim of this issue consists to point out the main advances in the HSCT setting.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.